Talaporfin

DB11812InvestigationalSmall molecule

Talaporfin has been investigated for the treatment of Port-Wine Stain and Benign Prostatic Hyperplasia.

Chemical structure of Talaporfin
Formula / weight
C38H41N5O9 · 711.772 g/mol (avg)

Resolves to

Compound
UNIIP4ROX5ELT2CAS110230-98-3ChEMBLCHEMBL2111186ChEBI135875PubChem5486799
Structure
InChIKeyVSEIDZLLWQQJGK-WSUYNKMOSA-NSMILESCCC1=C(C)\C2=C\C3=C(C=C)C(C)=C(N3)\C=C3/N=C([C@@H](CCC(O)=O)[C@@H]3C)/C(/CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C3\N\C(=C/C1=N2)C(C)=C3C(O)=O

What you can answer from here — as of September 23, 2026

43Drug interactionsStructured to mechanism, not free text
Sign in
11Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which companies are running trials of Talaporfin, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In